Health-Related Quality of Life in Patients With Different Diseases Measured With the EQ-5D-5L: A Systematic Review

Zhou, Ting; Guan, Haijing; Wang, Luying; Zhang, Yao; Rui, Mingjun; Ma, Anlin

doi:10.3389/fpubh.2021.675523

Cited by 82 publications

(65 citation statements)

References 109 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition, this review highlights that, while many instruments could be used to evaluate HRQoL, a vast majority of these instruments are generic. The EQ-5D questionnaire, for instance, is said to be one of the most prevalent ways to measure HRQoL worldwide ( Zhou et al, 2021 ). However, it could be argued that these generic measurement tools are limited to a certain number of health dimensions and may therefore miss important aspects of QoL to the profit of general health status regardless of disease’s specificities ( Mossman et al, 2016 ; Efthymiadou et al, 2019 ).…”

Section: Discussionmentioning

confidence: 99%

Valuing the “Burden” and Impact of Rare Diseases: A Scoping Review

2022

View full text Add to dashboard Cite

Introduction: Rare diseases (RDs) are a severe, chronic, degenerative and often life-threatening group of conditions affecting more than 30 million people in Europe. Their impact is often underreported and ranges from psychological and physical symptoms seriously compromising quality of life. There is then a need to consolidate knowledge on the economic, social, and quality of life impacts of rare diseases.Methods: This scoping review is the result of 9 qualitative interviews with experts and a literature search on Cost-of-Illness (COI) studies and quality of life (QoL) studies following the PRISMA methodology. Grey literature was also included to complement findings. Results. 63 COI studies were retrieved, covering 42 diseases and a vast majority of them using a prevalence-based approach (94%). All studies included medical costs, while 60% included non-medical costs, 68% productivity losses and 43% informal care costs. 56 studies on QoL were retrieved, mostly from Europe, with 30 different measurement tools. Grey literature included surveys from the pharmaceutical industry and patient organisations.Discussion: The majority of studies evaluating the impact of RDs on the individual and society use the COI approach, mostly from a societal perspective. Studies often vary in scope, making them difficult to consolidate or compare results. While medical costs and productivity losses are consistently included, QoL aspects are rarely considered in COI and are usually measured through generic tools.Conclusion: A comprehensive study on impact of rare disease across countries in Europe is lacking. Existing studies are heterogeneous in their scope and methodology and often lack a holistic picture of the impact of rare. Consensus on standards and methodology across countries and diseases is then needed. Studies that consider a holistic approach are often conducted by pharmaceutical companies and patient organisations exploring a specific disease area but are not necessarily visible in the literature and could benefit from the sharing of standards and best practices.

show abstract

Section: Discussionmentioning

confidence: 99%

Valuing the “Burden” and Impact of Rare Diseases: A Scoping Review

2022

View full text Add to dashboard Cite

show abstract

“…The European Quality‐of‐Life 5‐Dimension 5‐Level (EQ‐5D‐5L) is a generic measure of HRQL; it is a widely used questionnaire in different diseases and in PLWH. [ 18 ] The questionnaire consists of five different dimensions, an overall value (utility index [UI] value), and the visual analog scale (VAS) to assess the patient’s current health state. [ 16 ] A perception of poor health may negatively influence self‐care and adherence to treatment, and in this context an HRQL assessment may predict survival in PLWH.…”

Section: Introductionmentioning

confidence: 99%

Effect of hepatic steatosis and associated metabolic comorbidities on health‐related quality of life in people living with HIV

et al. 2022

View full text Add to dashboard Cite

Hepatic steatosis (HS) related to nonalcoholic fatty liver disease (NAFLD) is increasing globally. In people living with human immunodeficiency virus (PLWH) risk factors of HS are increased. The impact of HS on outcomes and in particular health‐related quality of life (HRQL) in PLWH remains unknown. The aim of this cross‐sectional cohort study (FLASH, Prevalence of Advanced Fibrosis in Patients Living With HIV) was to determine the contribution of HS on HRQL in PLWH and to identify confounders on HRQL. A total of 245 PLWH were prospectively enrolled. HS was assessed using vibration‐controlled transient elastography and defined as a controlled attenuation parameter (CAP) of ≥ 275 dB/m. The analysis was performed between CAP < 275 and ≥ 275 dB/m. The generic European Quality‐of‐Life 5‐Dimension 5‐Level questionnaire was used to determine differences in the HRQL. Univariable and multivariable linear regression models were applied to identify predictors with impaired HRQL in both groups. In this cohort, 65% (n = 160) presented without and 35% (n = 85) with HS, of whom most had NAFLD (n = 65, 76.5%). The HRQL (UI‐value) was significantly lower in PLWH and steatosis (0.86 ± 0.18) in comparison with no steatosis (0.92 ± 0.13). Unemployment (p = 0.025) and waist circumference (p = 0.017) remained independent predictors of a poor HRQL in the steatosis subgroup. In turn, age (p = 0.045), female sex (p = 0.030), body mass index (p = 0.010), and arterial hypertension (p = 0.025) were independent predictors of a low HRQL in the subgroup without steatosis. Conclusion: HS and metabolic comorbidities negatively affect the HRQL. Addressing these factors may improve patient‐reported and liver‐related outcomes in PLWH.

show abstract

“…The median health utility value of the patients with chronic pain reported in this study (0.669) is lower than that of the general Malaysian population (median: 1.0; IQR: 0.925, 1.075) [ 21 ], suggesting that chronic pain negatively affects quality of life. Furthermore, it is noted that chronic pain affected HRQoL to a greater extent as compared with other diseases, such as diabetes mellitus, cardiovascular diseases, chronic obstructive pneumonia disease, human immunodeficiency virus infection, chronic kidney disease and neoplasm [ 28 ]. This could be due to the various consequences of chronic pain, which compromise not only one’s physical function but also social life [ 10 ].…”

Section: Discussionmentioning

confidence: 99%

Health-related quality of life of Malaysian patients with chronic non-malignant pain and its associated factors: a cross-sectional study

Ang

Leong

Chan

et al. 2022

BMC Musculoskelet Disord

View full text Add to dashboard Cite

Background Chronic pain has a major impact on a patient’s quality of life, affecting physical and psychological functioning. It has debilitating consequences on social and economic aspects too. This study aimed to explore the status of health-related quality of life (HRQoL) of Malaysian patients suffering from chronic non-malignant pain. Methods Four hospitals offering pain clinic services were involved in this multicentre cross-sectional study conducted between June and September 2020. Adult patients who had been diagnosed with non-malignant chronic pain lasting for at least three months and able to communicate in English or Malay language were recruited in this study. Participants were informed about the study and were made aware that their participation was entirely voluntary. A battery of questionnaires consists of the EuroQol-5 dimensions-5 levels questionnaire (EQ-5D-5L) and the EuroQol visual analogue scale (EQ VAS), the Pain Self-Efficacy questionnaire (PSEQ) and the Pain Catastrophizing Scale (PCS) were self-administered by the patients. Besides, a structured questionnaire was used to collect their socio-demographic information, pain condition, sleep quality and working status. Participants’ usage of pain medications was quantified using the Quantitative Analgesic Questionnaire (QAQ). Results A total of 255 patients participated in this study. A median EQ-5D index value of 0.669 (IQR: 0.475, 0.799) and a median EQ VAS score of 60.0 (IQR: 50.0, 80.0) were recorded. Malay ethnicity (Adj. B: 0.77; 95% CI: 0.029, 0.126; p = 0.002) and a higher level of self-efficacy (Adj. B: 0.008; 95% CI: 0.006, 0.011; p < 0.001) were predictors of a better HRQoL, while suffering from pain in the back and lower limb region (Adj. B: -0.089; 95% CI: − 0.142, − 0.036; p = 0.001), the use of a larger amount of pain medications (Adj. B: -0.013; 95% CI: − 0.019, − 0.006; p < 0.001), and a higher degree of pain magnification (Adj. B: -0.015; 95% CI: − 0.023, − 0.008; p < 0.001) were associated with a poorer HRQoL. Conclusions These findings suggested that Malay ethnicity and a higher level of self-efficacy were predictors of a better HRQoL in patients with chronic pain, whereas pain-related factors such as higher usage of medication, specific pain site and pain magnification style were predictors of poorer HRQoL.

show abstract

Health-Related Quality of Life in Patients With Different Diseases Measured With the EQ-5D-5L: A Systematic Review

Cited by 82 publications

References 109 publications

Valuing the “Burden” and Impact of Rare Diseases: A Scoping Review

Valuing the “Burden” and Impact of Rare Diseases: A Scoping Review

Effect of hepatic steatosis and associated metabolic comorbidities on health‐related quality of life in people living with HIV

Health-related quality of life of Malaysian patients with chronic non-malignant pain and its associated factors: a cross-sectional study

Contact Info

Product

Resources

About